Belatacept

Drug Profile

Belatacept

Alternative Names: BMS-224818; CTLA4-IgLEA29Y; LEA 29Y; Nulojix

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Emory University
  • Class Drug conjugates; Immunoconjugates; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action CD28 antigen inhibitors; CD80 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Discontinued Liver transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 11 Jul 2016 Efficacy and adverse events data from the BENEFIT-EXT trial in Renal transpant rejection (prevention) presented 26th International Congress of the Transplantation Society
  • 01 Dec 2015 Bristol-Myers Squibb initiates enrolment in a phase II trial for Renal transplant rejection (combination therapy; prevention) in Germany, Austria, USA and Argentina (NCT02137239)
  • 29 Sep 2015 Bristol-Myers Squibb plans a phase I pharmacokinetics trial in Healthy volunteers in USA (NCT02564497)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top